Design Therapeutics, Inc.
NASDAQ:DSGN
5.54 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.001 |
| Cost of Revenue
| 0.537 | 0.466 | 0.129 | 0.005 | 0.002 |
| Gross Profit
| -0.537 | -0.466 | -0.129 | -0.005 | -0.001 |
| Gross Profit Ratio
| 0 | 0 | 0 | -21.124 | -0.983 |
| Reseach & Development Expenses
| 57.063 | 48.613 | 24.778 | 6.06 | 1.654 |
| General & Administrative Expenses
| 21.127 | 18.98 | 11.053 | 2.496 | 1.088 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 21.127 | 18.98 | 11.053 | 2.496 | 1.088 |
| Other Expenses
| 0 | 4.285 | 0.298 | -0.226 | -0.834 |
| Operating Expenses
| 78.19 | 67.593 | 35.831 | 8.33 | 1.908 |
| Operating Income
| -78.19 | -67.593 | -35.831 | -8.33 | -1.908 |
| Operating Income Ratio
| 0 | 0 | 0 | -36,858.407 | -2,287.77 |
| Total Other Income Expenses Net
| 11.328 | 4.285 | 0.298 | 0.05 | -0.139 |
| Income Before Tax
| -66.862 | -63.308 | -35.533 | -8.28 | -2.047 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -36,637.168 | -2,454.436 |
| Income Tax Expense
| -0.537 | -4.691 | -0.108 | -0.201 | -0.002 |
| Net Income
| -66.862 | -58.617 | -35.533 | -8.28 | -2.047 |
| Net Income Ratio
| 0 | 0 | 0 | -36,637.168 | -2,454.436 |
| EPS
| -1.19 | -1.05 | -0.77 | -0.3 | -0.075 |
| EPS Diluted
| -1.19 | -1.05 | -0.77 | -0.3 | -0.075 |
| EBITDA
| -78.19 | -67.593 | -35.702 | -8.325 | -1.908 |
| EBITDA Ratio
| 0 | 0 | 0 | -36,836.283 | -2,287.77 |